AstraZeneca (AZN.US) faces setback in Phase III clinical trial of breast cancer drug Etcamah, potentially impacting billions of dollars in sales

According to Zhitong Finance APP, AstraZeneca (AZN.US) announced last Friday that its oral selective estrogen receptor degrader (SERD) Etcamah (camizestrant) combined with Palbociclib for first-line treatment of ER-positive, HER2-negative advanced breast cancer in the SERENA-4 phase III trial did not meet the primary endpoint. Although there was a numerical improvement in progression-free survival (PFS), it did not reach statistical significance.